Francisco Trust, recognized as a ten percent owner of Dyadic International Inc. (NASDAQ:DYAI), has formally documented the liquidation of a substantial portion of its equity position. The entity reported the sale of 172,864 common shares, generating a total transaction value of $343,763. These dispositions were executed across multiple dates spanning from June 6, 2024, through January 7, 2025. The shares were divested at varying price points, with the transaction prices ranging between $1.8024 and $2.4264 per share.
Following the completion of these sales, Francisco Trust retains a direct position in 3,375,664 shares of Dyadic International common stock. The current market valuation for the equity stands at $0.94 per share, a figure that sits significantly below the historical sale prices executed by the trust. Market analysis indicates that the company may be trading at a discount relative to its estimated fair value, despite the ongoing insider liquidation activity.
Beyond the direct equity sales, Francisco Trust's relationship with Dyadic International involves complex financial instruments, specifically a senior secured convertible promissory note. On March 8, 2024, Dyadic International issued an 8.0% senior secured convertible promissory note to the trust. The initial terms of this instrument allowed for conversion at $1.79 per share, resulting in an initial convertible position of 558,659 shares. The original maturity date for this obligation was set for March 8, 2027.
The structural terms of this convertible note have undergone significant revision. On October 4, 2024, the conversion price was adjusted downward to $1.40 per share. This amendment effectively increased the total number of shares underlying the note to 714,286. A subsequent modification on December 23, 2025, further reduced the conversion price to $1.05 per share. This latest adjustment expands the convertible share count to 952,381 shares of common stock. The maturity date for the note was simultaneously extended to December 31, 2027.
Operational metrics for Dyadic International reveal a notable expansion in top-line revenue. For the first quarter of 2026, the company reported revenue of $1.1 million, representing an 182% year-over-year increase. Despite this substantial revenue growth, the company's profitability metrics remained constrained. Earnings per share (EPS) held flat at a loss of $0.05, a result that aligns with existing analyst forecasts for the period.
In parallel with financial reporting, Dyadic International received regulatory confirmation regarding its intellectual property portfolio. The Japan Patent Office granted claims related to the company's Thermothelomyces heterothallica recombinant protein expression technology. This patent protection covers critical aspects of the protein expression technology utilized across various life sciences and biopharmaceutical applications.
Corporate governance structures were also updated during the 2026 Annual Meeting of Shareholders. Seth J. Herbst, M.D., was elected to the board of directors as a Class I director, with a term extending until the 2029 Annual Meeting. The meeting also facilitated approvals for a reverse stock split and the appointment of a new auditor. These governance adjustments reflect ongoing efforts to manage corporate structure and operational efficiency.
The intersection of insider selling, convertible note restructuring, and operational growth presents a complex valuation scenario for Dyadic International. While revenue expansion is evident, the persistence of losses and the specific terms of debt instruments require careful monitoring by market participants.